Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II

Executive Summary

DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.

You may also be interested in...



Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line

Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.

Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003

The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.

Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line

Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.

Related Content

UsernamePublicRestriction

Register

PS037649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel